Matthew Kapusta Sells 41,671 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 41,671 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $50.00, for a total value of $2,083,550.00. Following the sale, the chief executive officer directly owned 521,795 shares of the company’s stock, valued at approximately $26,089,750. This represents a 7.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $49.04 on Wednesday. The stock’s fifty day simple moving average is $25.97 and its 200 day simple moving average is $22.47. The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of -14.09 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. As a group, sell-side analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On uniQure

Hedge funds have recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its stake in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 533 shares in the last quarter. Arizona State Retirement System raised its stake in uniQure by 6.0% during the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 627 shares in the last quarter. Ensign Peak Advisors Inc lifted its holdings in shares of uniQure by 21.7% during the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after acquiring an additional 650 shares during the period. Finally, FNY Investment Advisers LLC lifted its holdings in shares of uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 718 shares during the period. 78.83% of the stock is currently owned by institutional investors.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported promising early results from its AMT-260 epilepsy program, with initial patients showing large seizure reductions and no treatment-related serious adverse events, supporting confidence in the company’s gene-therapy pipeline. Article Title
• Positive Sentiment: Several news outlets highlighted early AMT-260 data showing seizure reductions of 79% to 100% in three patients, which is helping fuel investor enthusiasm for the stock. Article Title
• Positive Sentiment: Analysts remain bullish on QURE, with recent upgrades and higher price targets reinforcing the view that the latest pipeline progress could create additional upside. Article Title
• Neutral Sentiment: The company also announced preliminary Phase I/IIa data for AMT-260, which is an important but expected clinical milestone for a development-stage biotech. Article Title
• Negative Sentiment: uniQure launched a proposed $150 million public offering, plus a potential $22.5 million greenshoe, which could dilute existing shareholders even as it strengthens the balance sheet. Article Title
• Negative Sentiment: Recent insider selling by the CEO and two directors may weigh on sentiment, even though the trades were made under pre-arranged 10b5-1 plans. Article Title

Analyst Upgrades and Downgrades

QURE has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating on shares of uniQure in a research report on Thursday, June 18th. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research note on Wednesday, June 17th. Royal Bank Of Canada increased their price objective on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. The Goldman Sachs Group lifted their price objective on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research report on Thursday, June 18th. Finally, Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $25.00 to $65.00 in a research note on Thursday, June 18th. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $58.92.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.